Xenitra locks in A$12M OTC pharmaceutical offtake deal with Chinese distribution giant Kangsheng
Xenitra Limited (ASX:XEN) has signed a three-year OTC pharmaceutical procurement agreement with Kangsheng Hong Kong International Trading Limited, delivering a minimum of A$12 million in sales to the company over the term.
The agreement is fulfilled through individual purchase orders placed with Xenitra’s recently acquired subsidiary, Hong Kong Fukang Trading Co., Limited (Fukang), which acts as seller, with Kangsheng as buyer.
The deal marks the first major commercial agreement of Xenitra’s OTC pharmaceuticals division, a key growth pillar of the company’s three-pillar growth strategy. Initial commercial orders are expected to commence this quarter (Q1 FY27) following completion of operational onboarding.
When big ASX news breaks, our subscribers know first
The deal at a glance: what Xenitra has secured
The agreement establishes a three-year strategic cooperation framework covering pharmaceutical product supply, channel development, operational support and long-term market expansion across China and the Asia-Pacific. Orders are intended to be progressed quarterly and annually.
| Key Term | Summary |
|---|---|
| Parties | Seller: Hong Kong Fukang Trade Limited. Buyer: Hong Kong Kangsheng International Co., Limited. |
| Procurement objective | Kangsheng to purchase not less than A$12 million, or the equivalent in US dollars, of pharmaceutical and health products over the three-year term. |
| Term | Three years, stated to run from July 2026 to July 2029. May continue after expiry if parties keep trading, subject to 30 days’ written termination notice. |
| Governing law | Signed in Hong Kong; refers to the PRC Civil Code and Hong Kong commercial law. |
| Products | Global compliant prescription medicines, OTC medicines and broader health products, with a focus on products sourced from Australia, Europe and other international markets. |
| Supply relationship | Fukang designated a core priority pharmaceutical supply-chain partner. Kangsheng may use other suppliers where Fukang has no stock, lacks valid qualifications, or pricing is materially outside the market and cannot be agreed. |
| Payment terms | Staged: 20% deposit after order confirmation, 30% after dispatch, and the remaining 50% within three working days after receipt, inspection and document verification. |
Why this matters for investors
The agreement carries three clear implications for shareholders:
-
It moves the OTC pillar from preparatory investment (wholesale distribution licensing and the Fukang acquisition) into a contracted commercial relationship carrying a cumulative procurement minimum target of A$12 million over three years.
-
It provides an immediate route to market in China’s healthcare consumption market via an established omnichannel network. Building comparable reach organically could take years; this agreement provides it through an established partner.
-
It offers external validation. Kangsheng advises annual sales of approximately RMB900 million (~A$190 million) across e-commerce platforms and retail pharmacies, a figure provided by Kangsheng to Xenitra. A counterparty of that scale electing to partner with Xenitra is described as a meaningful endorsement of the company’s sourcing capability and distribution model.
Taken together, all three growth pillars are advancing in parallel rather than sequentially, giving shareholders multiple, concurrent avenues for value creation.
Non-Executive Chairman, Dr Anthony Noble
“Today’s announcement represents another important execution milestone for Tracy Zhang and her team in China. In terms of Xenitra’s core strategy, this deal demonstrates concrete delivery against the third and final growth pillar. Taken together with the explosive growth after launch of the OPAL tokenised sales division, this deal demonstrates that the company is now delivering on all parts of the new long-term growth strategy, as we enter FY27.”
Understanding China’s OTC and cross-border healthcare market
In China, imported OTC products and health goods are increasingly sold through cross-border channels, spanning e-commerce platforms, livestream commerce and retail pharmacy networks, often referred to as an omnichannel model.
Demand is supported by structural tailwinds: an ageing population, rising health awareness, and sustained appetite for quality-assured imported health products. For a company entering this market, a distribution-ready partner such as Kangsheng offers established reach that would otherwise take years to build.
How the OTC deal fits Xenitra’s three-pillar strategy
Xenitra’s healthcare strategy is built on three complementary growth pillars, each now underpinned by live commercial activity:
-
OTC pharmaceuticals — now entering commercial operations at meaningful scale via the Kangsheng-Fukang agreement.
-
Nutritionals — well established and underpinned by the $30 million per annum partnership with Rockcheck.
-
OPAL RWA tokenised sales ecosystem — described by the company as showing rapid growth in high-margin sales.
According to Dr Noble, the company has successfully transitioned all three strategic business pillars from concept into execution over 2026 and enters the new financial year operating with a much leaner cost base. Xenitra is described as one of the first Australian companies to commercially deploy Real World Asset (RWA) tokenisation integrated directly into mainstream FMCG sales channels in China.
What comes next
Initial commercial orders are expected to commence this quarter (Q1 FY27) following completion of operational onboarding, with orders intended to be progressed on a quarterly and annual basis.
Management positions the agreement as a potential foundation for a deeper strategic partnership across the OTC medicine commercial platform, with intended expansion of Xenitra’s FMCG and healthcare business throughout the Asia-Pacific region. The announcement does not disclose specific revenue phasing beyond the quarterly and annual order cadence.
Don’t Miss the Next Healthcare Stock Moving on ASX News
Big News Blast delivers FREE breaking ASX healthcare announcements directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000 active subscribers are already getting the edge on market-moving news the moment it drops. Click the “Free Alerts” button at StockWire X to start receiving alerts today.